Novamind working with Center for Change to treat patients, conduct research
- Collaboration with Center for Change examines the novel use of Novamind’s ketamine-assisted psychotherapy (“KAP”) protocols for the treatment of eating disorders
- Shared preliminary findings from two studies using ketamine-assisted psychotherapy protocols to treat eating disorders: Emotion-Focused Ketamine-Assisted Psychotherapy (EF-KAP) and Group-based Ketamine-Assisted Psychotherapy (G-KAP)
- There are no FDA-approved medication options currently available for individuals suffering from Anorexia Nervosa, an often-debilitating mental health condition
TORONTO, ON / April 21, 2021 / Novamind Inc. (CSE:NM)(OTC PINK:NVMDF)(FSE:HN2) (“Novamind” or the “Company”), a leading mental health company specialized in psychedelic medicine, has shared preliminary findings from two studies using ketamine-assisted psychotherapy protocols to treat eating disorders: Emotion-Focused Ketamine-Assisted Psychotherapy (EF-KAP) and Group-based Ketamine-Assisted Psychotherapy (G-KAP). Novamind collaborated on the study with Center for Change, a specialty psychiatric hospital and leading treatment facility for eating disorders.
In a webinar held by Center for Change on April 8th, 2021, Dr. Reid Robison, Novamind’s Chief Medical Officer, discussed early findings from the two studies for eating disorders. The collaboration with Center for Change examines the novel use of Novamind’s ketamine-assisted psychotherapy (“KAP”) protocols for the treatment of eating disorders. There are no FDA-approved medication options currently available for individuals suffering from Anorexia Nervosa, an often-debilitating mental health condition.
“Novamind is dedicated to researching, developing and delivering new therapeutic protocols to answer unmet needs in mental healthcare,” said Dr. Robison, who also serves as Medical Director for Center for Change. “Our treatment protocols are designed to improve patient outcomes, and we’re proud that renowned facilities like Center for Change recognize that we can provide new options for individuals struggling with eating disorders.”
Novamind offers its clients access to several KAP protocols through Cedar Psychiatry, its wholly owned network of psychiatry clinics. Specialized KAP protocols currently available at Cedar Psychiatry include Emotion-Focused Ketamine-Assisted Psychotherapy and Group Ketamine-Assisted Psychotherapy. Cedar Psychiatry has administered over 7,000 ketamine treatments since 2016 and is undergoing an expansion of its clinic network in the United States.
“Novamind’s psychedelic protocols are informed by the expertise gained from our operating clinics, as well as collaborating with leading medical institutions. We’re pleased to work with Center for Change to advance innovation in mental healthcare,” said Yaron Conforti, CEO and Director of Novamind.
About Novamind
Novamind is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics, retreats, and clinical research sites. Novamind provides ketamine-assisted psychotherapy and other novel treatments through its network of Cedar Psychiatry clinics and operates Cedar Clinical Research, a contract research organization specialized in clinical trials and evidence-based research for psychedelic medicine. Both Cedar Psychiatry and Cedar Clinical Research are wholly owned subsidiaries of Novamind. For more information on how Novamind is enhancing mental wellness and guiding people through their entire healing journey, visit novamind.ca.
About Center for Change
Center for Change was founded on October 28th, 1994, by a team of psychologists and a physician with a long history together. From those first days, Center for Change began to design the current facility and develop its core treatment programs. A handpicked team of experts forms the backbone of what we do, and they are committed to helping each person get back their life and restore a sense of freedom that may have been absent for far too long.
The Center is licensed with the State of Utah as a Specialty Psychiatric Hospital, and in April 1998, Center for Change received accreditation from The Joint Commission. This accreditation is limited to top organizations delivering high levels of patient service, reducing patient risk and creating an environment for continuous improvement. The Joint Commission has recognized Center for Change for its high standards of patient care and commitment to ongoing education.
Contact Information
Novamind
Yaron Conforti, CEO and Director
Telephone: +1 (647) 953 9512
Bill Mitoulas, Investor Relations
Email: [email protected]
Center for Change
Tamara Bingham Noyes, Director of Business Development
Telephone: +1 (888) 224 8250 ext. 267
Email: [email protected]
Forward-Looking Statements
This news release contains forward-looking statements. All statements other than statements of historical fact included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations including the risks detailed from time to time in the Company’s public disclosure. The reader is cautioned not to place undue reliance on any forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable laws.
SOURCE: Novamind Inc.
